

Maria Rosa Bani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522485/publications.pdf>

Version: 2024-02-01

40
papers

1,860
citations

257450

24
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

2664
citing authors

#	ARTICLE	IF	CITATIONS
1	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 555-567.	4.1	11
2	PGC1 α / β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1423-1434.	0.9	14
3	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. <i>Journal of Hematology and Oncology</i> , 2021, 14, 186.	17.0	27
4	Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 572-580.	1.4	6
5	Targeting melanoma stem cells with the Vitamin E derivative γ -tocotrienol. <i>Scientific Reports</i> , 2018, 8, 587.	3.3	46
6	Soluble stroma-related biomarkers of pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	56
7	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018, 143, 2187-2199.	5.1	8
8	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017, 20, 233-241.	7.2	22
9	Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. <i>Cancer Research</i> , 2017, 77, 6759-6769.	0.9	4
10	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. <i>Connective Tissue Research</i> , 2015, 56, 355-363.	2.3	10
11	Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 73-81.	3.3	45
12	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. <i>Oncotarget</i> , 2015, 6, 3043-3054.	1.8	38
13	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. <i>Oncotarget</i> , 2015, 6, 28389-28400.	1.8	13
14	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. <i>Cancer Research</i> , 2014, 74, 6980-6990.	0.9	110
15	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts. <i>Cancer Research</i> , 2012, 72, 1814-1824.	0.9	86
16	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1167-1178.	5.4	40
17	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. <i>British Journal of Dermatology</i> , 2011, 164, 1061-1070.	1.5	25
18	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 43-53.	3.3	18

#	ARTICLE	IF	CITATIONS
19	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. <i>Endocrinology</i> , 2010, 151, 4643-4653.	2.8	15
20	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. <i>BMC Genomics</i> , 2008, 9, 201.	2.8	56
21	Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 481-488.	5.9	12
22	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1839-1849.	7.0	54
23	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 715-725.	4.1	27
24	Invasion and Metastasis. , 2004, , 443-461.		4
25	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 111-21.	4.1	46
26	Anticancer Therapy with Angiogenesis Inhibitors. <i>Tumori</i> , 2001, 87, 14-16.	1.1	1
27	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300.	5.9	51
28	Inhibition of matrix metalloproteinases by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. <i>International Journal of Cancer</i> , 2001, 91, 241-247.	5.1	29
29	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. <i>Oncogene</i> , 2000, 19, 395-402.	5.9	50
30	The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. <i>Oncogene</i> , 2000, 19, 1419-1427.	5.9	26
31	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394.	2.6	43
32	Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. <i>British Journal of Cancer</i> , 1999, 80, 504-512.	6.4	59
33	Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 655-662.	3.3	35
34	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome-Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. <i>Blood</i> , 1999, 94, 1747-1754.	1.4	5
35	Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. <i>Nature Genetics</i> , 1998, 19, 199-202.	21.4	267
36	The A1 and A1B proteins of heterogeneous nuclear ribonucleoproteins modulate 5' splice site selection in vivo.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 6924-6928.	7.1	189

#	ARTICLE	IF	CITATIONS
37	Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8398-8402.	7.1	129
38	Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: evidence that A1 is not essential for cell growth.. Molecular and Cellular Biology, 1992, 12, 4449-4455.	2.3	82
39	Blood coagulation changes in nude mice bearing human colon carcinomas. International Journal of Cancer, 1992, 50, 75-79.	5.1	13
40	Effect of Interleukin-1-beta on Metastasis Formation in Different Tumor Systems. Journal of the National Cancer Institute, 1991, 83, 119-123.	6.3	84